“The existing (heart failure) therapies are essentially diuretics reducing total circulating volume (SGLT2 inhibitors and Entresto). This reduction in preload prevents backflow into the lungs from a dilated non compliant left ventricle, and reduces symptomatic shortness of breath. MSB’s Rexlemestrocel doesn’t have any effect on preload, but it reduces left ventricular inflammation, improves micro vascular flow and protects viable cardiomyocytes against death. That increases contractility and forward flow, resulting in reduction of heart attacks, strokes and death.” - Dr. Itescu on the mechanism of action
”With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.” - Dr. Perin (extract from above link)
MSB Price at posting:
37.0¢ Sentiment: Hold Disclosure: Held
(20min delay)